A fixed combination of 2 drugs in one pill.
Sold as EluRyng, Enilloring, Haloette, NuvaRing.
A combination is graded by its riskiest ingredient: each part of the score is the lowest of the ingredients' scores. This grade answers one narrow question: how strong is the public evidence and safety record behind this drug, and how clean is its money trail and court record? It is not a verdict on whether the drug is right for you.
Each ingredient has its own full page with the FDA label, side-effect reports, recalls, evidence, and payments. Open them for the detail behind this grade.
Score breakdown (59/100)
Safety ×35%
D
Evidence ×25%
F
Regulatory ×15%
B
Money & lawsuits ×15%
C
Options ×10%
C
Safety: 58
Graded by its riskiest ingredient, ethinyl estradiol (58)
Carries an FDA boxed warning, the strongest warning the FDA issues (-30)
Death appears in 2.6x the share of reports seen across all of FAERS (-12)
Evidence: 38
Graded by its riskiest ingredient, ethinyl estradiol (38)
187 randomized trials and 2 systematic reviews/meta-analyses indexed in PubMed
No Cochrane review found (-5)
Only 32% of completed registered trials posted results (-15)
Regulatory history: 81
Graded by its riskiest ingredient, etonogestrel (81)
No recalls on record since 2016
REMS program in force (-10)
4 label changes approved since 2021 (-4)
Label lists recent major changes to warnings or indications (-5)
Money & lawsuits: 70
Graded by its riskiest ingredient, etonogestrel (70)
Pharma paid doctors $2,184,034 tied to this drug last year (-30)
Not named in any pending federal MDL
Options: 70
Graded by its riskiest ingredient, ethinyl estradiol (70)
No generic version approved: brand-only pricing (-30)
10 same-class alternatives exist
Money and lawsuits
In 2024, drug companies reported $6,936 in payments to US physicians and hospitals tied to this combination's brands across 447 transactions (NuvaRing $6,936).
No pending federal MDL names this combination or its brands.
The ingredients' own payments and lawsuits are on their pages and already count toward this grade.
Who takes it and what it costs
2,950Medicare Part D patients (2024)
8,012prescriptions filled
$196average cost per fill
$2Mtotal Medicare spend
Product
Fills
$/fill
Etonogestrel-Ethinyl Estradiol
3,388
$196
Eluryng
2,065
$169
Enilloring
1,126
$172
Haloette
913
$214
Nuvaring
520
$323
Questions to ask your prescriber
This is a fixed combination of ethinyl estradiol and etonogestrel. Why both together, instead of only the one I need?
This drug carries a boxed warning. Which specific risk does it cover, and does it apply to me?
The most-reported problems in FDA's adverse event data are pain, lower respiratory tract infection, pruritus, rash. How would we recognize and handle those?
Why this one over chlorotrianisene, diethylstilbestrol, estetrol? What would make you pick one of those instead?
There is no generic. Is there an older generic in the same class that works as well for my situation?
What result are we expecting, by when, and what is the plan if it does not happen?
If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)
This drug has a REMS safety program. What monitoring does that require from us?
The most-reported problems in FDA's adverse event data are no adverse event, complication associated with device, product quality issue, device breakage. How would we recognize and handle those?
Why this one over desogestrel, drospirenone, levonorgestrel? What would make you pick one of those instead?
The manufacturer pays physicians heavily to promote this drug. Have you received anything from them?